BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

Activity among biotech IPOs has reached a steady drip following a slowdown for several weeks as COVID-19’s spread roiled markets earlier this year. The latest to file for a NASDAQ listing is Pliant, a clinical...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

Even if COVID-19 does disrupt operations or create a buyer’s market, Novartis will not veer from its business development strategy. The pharma was already expanding external innovation before the crisis, and has no intention of...
BioCentury | Mar 3, 2020
Finance

Pliant to advance rare fibrosis pipeline with Novartis-led $100M C round

A $100 million series C round led by Novartis and backed by multiple crossover investors gives Third Rock-founded Pliant ample cash to push forward with multiple fibrosis programs. The cash bolus comes less than half...
BC Extra | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BC Innovations | Nov 14, 2019
Targets & Mechanisms

Impaired wound healing: CD47’s latest safety hurdle?

Just as anti-CD47 antibodies are getting past their first safety hurdle of hematological toxicities, a new study has cautioned that the antibodies could have a dangerous effect on wound healing. In a paper published in...
BC Innovations | Oct 28, 2019
Distillery Therapeutics

CD49e/CD61 inhibition for breast cancer and melanoma

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; melanoma Inhibition of CD49e/CD61 alone or in combination with anti-PD-1 therapies could treat breast cancer and melanoma. An siRNA against CD49e/CD61 reduced tumor volume in mice with breast cancer....
BioCentury | Oct 25, 2019
Product Development

Deciding factors in the shifting MS treatment landscape

The efficacy and convenience advantages that established oral medicines as the go-to therapy in multiple sclerosis are the same factors now squeezing them out. Two years post-launch, the success of injectable Ocrevus ocrelizumab from Roche...
BC Extra | Oct 23, 2019
Company News

Pliant to flesh out fibrosis pipeline after NASH deal with Novartis

Pliant’s deal to out-license its NASH candidate to Novartis for $80 million will allow the fibrosis company to fund development of its lead candidate, as well as advance its preclinical pipeline. Novartis AG (NYSE:NVS; SIX:NOVN)...
BC Extra | Oct 23, 2019
Company News

Oct. 22 Company Quick Takes: Zealand acquires Encycle; plus Novartis, Vitalis, Roche-Spark

Zealand expands peptide platform with Encycle acquisition  Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will expand its peptide therapeutics platform through the acquisition of Encycle Therapeutics Inc. In return for all its outstanding shares, access...
BC Innovations | Sep 19, 2019
Product Development

Anokion puts liver to the test

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance. Armed with a fresh $40 million series B round, Anokion S.A. is developing...
Items per page:
1 - 10 of 1008